What is the main business of Beit Jala Pharmaceutical Company?

The main business activity of Beit Jala Pharmaceutical Company focuses on wholesale of pharmaceutical goods.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on December 21, 2010.

Where is the headquarters located?

The headquarters is located at: Rondo Onz 1, 00-124 Warszawa.

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2020 to December 31, 2020.

What revenue was generated?

In 2020, the company generated total revenue of $16, representing a decrease of 96.5% compared to 2019.

No, the company recorded a net loss of $7,302 in 2020. For comparison, in 2019 the loss was $3,294, meaning the company increased its loss by 125.2%.

What is the main operating cost?

The largest operating cost category falls under other operating costs. This category amounted to $3,655 in 2020, representing 100% of all operating expenses.

Beit Jala Pharmaceutical Companysp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2010-12-21

Share capital

5,000.00 PLN

Registered address

Rondo Onz 1/Xxp., 00-124 Warszawa, Poland

Financials

Revenue history

Filing timeliness

No financial statement for 2021 – the filing deadline has passed. 2 of 3 financial statements were filed late (the longest delay 583 days for 2018).

2021not filed
202017/09/2021
201917/02/2021
201817/02/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2020.

Results vs industry

Revenue

This companyUSD 16.05MedianUSD 1.06mAverageUSD 22.40m

Net profit

This companyUSD -7.30kMedianUSD 37.33kAverageUSD 880.24k

Operating costs

This companyUSD 3.66kMedianUSD 922.77kAverageUSD 21.08m

Assets

This companyUSD 9.89kMedianUSD 608.93kAverageUSD 11.85m

Industry

Authorized Representatives

Anjail Zaboora – Management Board Member

Manner of representation

If one member of the management board has been appointed, that member has the right to represent the company independently. If a multi-member management board has been appointed, joint action by two members of the management board or by one member of the management board and a commercial proxy is required to make declarations on behalf of the company.

Ownership

Owner	Shares	Share value	Stake
Beit Jala Pharmaceutical Company	100	$1,350.62	100%

Beneficial owners

No beneficial owners recorded for the company Beit Jala Pharmaceutical Company.

Bank accounts

Was a VAT taxpayer from 2013-02-15 to 2025-02-28.

Reason for removal: Art. 96 ust. 6-8

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Centrala Farmaceutyczna CefarmS.A.	$457,052,669.59	cefarm.com.pl
ITPS.A.	$55,285,362.18	itpsa.pl
IMC Impomed CentrumS.A.	$4,447,564.10	impomed.pl
Gtm-Mobil M-T T.Walisiewiczsp. k.	$3,438,533.82	gtmmobil.com.pl
Reynolds Medicalsp. z o.o.	$3,313,657.78	reymed.pl
Petronafsp. z o.o.	$2,499,010.09	petronaf.com
CryoprofilS.A.	$1,470,469.25	cryoprofil.pl
Novisc Pharmasp. z o.o.	$806,018.56	novisc.com
Jacek Waksmundzki Trust 2S.K.A.	$5,769.53	trust.pl
Optimedussp. z o.o.	$1.00	optimedus.pl

Change history

Date	Event
2015-07-09	PKD change (Removed: 18 codes)
2013-02-22	Name change (Mlv 29 → Beit Jala Pharmaceutical Company)
2013-02-22	PKD change (Added: 23 codes)
2010-12-21	Entered in the register

FAQ

Last updated: 2026-10-07